Tilmicosin 30% aqua-TRV belongs to antibacterial veterinary products of the macrolide group and has a broad spectrum of antimicrobial activity. It is compatible with sulfonamides, tetracyclines, nitrofurans, spectinomycin and coccidiostatics. Active against most gram-positive and some gram-negative microorganisms, including: gram-positive: aerobic cocci - Staphylococcus spp., Streptococcus spp.; anaerobic spore-forming bacteria - Clostridium spp.; facultative anaerobes - Arcanobacterium spp,, gram-negative: aerobic bacteria - Pasteurella spp., and Chlamydia spp., Actinobacillus pleuropneumonia, Mannheimia haemolytica, Brachyspira hyodysenteriae and Mycoplasma spp.
The mechanism of bacteriostatic action of tilmicosin is to block protein synthesis in a bacterial cell at the ribosomal level, as a result of the formation of a complex with the 508-subunit of ribosomes, but at high concentrations it can act as bactericidal agent.
Tilmicosin is intracellularly capable of penetrating and accumulating in alveolar macrophoges. Its concentration in the tissues of the respiratory system is 40 times higher than the MIC for mycoplasmas. Tilmicosin phosphate binds moderately to plasma proteins (less than 30%), which ensures its high degree of solubility in lipids and allows it to penetrate well into biological fluids and tissues.
After oral administration, tilmicosin is well absorbed in the gastrointestinal tract and penetrates into most organs and tissues of the body, reaching the highest concentrations in the lungs and blood serum after 2-3 hours, and is maintained at a therapeutic level for 18-24 hours. It is metabolized in the liver and excreted from the body of animals mainly unchanged, and partly in the form of metabolites with feces and partly with urine.
Tilmicosin 30% aqua-TRV, according to the degree of exposure is classified as a moderately hazardous substance (hazard class 3 according to GOST 12.1.007-76).
